Inferra AI / Company / ALNY / Slides
Alnylam Pharmaceuticals — Alnylam Q2 2026 Earnings Presentation › (company IR deck)
Alnylam Pharmaceuticals (ALNY) · 33 slides · Filed Oct 29, 2026
Every slide of this earnings presentation, with the text as published. Open the original deck ↗ · All ALNY deck slides
Slide 1 — Second Quarter 2026
1 © 2026 Alnylam Pharmaceuticals, Inc. July 30, 2026 Second Quarter 2026 Financial Results
Slide 2 — 2
2 Agenda Josh Brodsky Vice President, Investor Relations 01 Welcome Yvone Grenstret, M.D. Chief Executive Oficer 02 Overview Jef Poulton Chief Financial Oficer 03 Financial Sumary Tolga Tanguler Chief Comercial Oficer 04 Comercial Highlights Pushkal Garg, M.D. Chief Research & Development Oficer 05 R&D and Pipeline Perspective 06 Q&A Ses ion
Slide 3 — Alnylam Forward
3 Alnylam Forward - Loking Statements This presentation contains forward - loking statements within the meaning of Section 27 A of the Securities Act of 193 and Section 21 E of the Securities Exchange Act of 1934 . Al statements other than historical statements of fact regarding Alnylam‘s expectations, beliefs, goals, plans or prospects including, without limitation, statements regarding : Alnylam‘s ability to achieve the goals in its —Alnylam 2030 “ strategy, including to achieve global TR leadership, grow through sustainable inovation, and scale with discipline and agility, and to become the leading science - driven, fuly integrated biopharmaceutical company and to maximize the ful potential of RNAi therapeutics for patients ; the size and future growth of the patient population and market oportunity in ATR - CM ; the potential future suces of the AMVUTRA launch in ATR - CM, including the potential for continued growth and expansion of the franchise ; AMVUTTRA‘s potential as a first - line therapy for ATR - CM and the potential for robust growth in first - line starts to continue ; Alnylam‘s ability to expand the number of prescribers of AMVUTRA in the future and for prescribers‘ experience with AMVUTRA to translate into a strong preference ; Alnylam‘s ability to obtain regulatory aprovals for AMVUTRA in ATR - CM in mainland China and Macao and in other countries and teritories ; the potential for any of Alnylam‘s colaborations to achieve the goals for which they were established ; Alnylam‘s ability, through investments in diagnosis - enabling initiatives, to identify ATR - CM patients earlier, to expand the treatable ATR - CM population, and ultimately to improve ATR - CM patient outcomes ; the number of patients who wil be enroled in Alnylam‘s clinical trials, including the TRITON - CM trial ; the probability of suces of the TRITON - CM clinical trial of nucresiran in ATR - CM and any of Alnylam‘s other clinical trials ; the TR knockdown that patients treated with nucresiran are expected to experience ; the timing of initiation of, completion of enrolment in, or anouncement of results from, any of Alnylam‘s clinical trials ; the potential for any of Alnylam‘s product candidates to sucesfuly complete clinical development and to receive regulatory aproval and launch comercialy, and the timing of any such comercial launches ; the potential eficacy, treatment efect and product profiles of any of Alnylam‘s products and product candidates ; and Alnylam‘ projected comercial and financial performance, including the expected range for 2026 of TR net product revenues, Rare net product revenues, total net product revenues, net revenues from colaborations and royalties, and non - GAP R&D and SG&A expenses should be considered forward - loking statements . Actual results and future plans may difer materialy from those indicated by these forward - loking statements as a result of various important risks, uncertainties and other factors, including, without limitation, risks and uncertainties relating to : Alnylam‘s ability to sucesfuly execute on its —Alnylam 2030 “ strategy ; Alnylam‘s ability to sucesfuly launch, market and sel Alnylam‘ aproved products globaly, including AMVUTRA ; Alnylam‘s ability to discover and develop novel drug candidates and delivery aproaches and sucesfuly demonstrate the eficacy and safety of its product candidates ; the pre - clinical and clinical results for Alnylam‘s product candidates ; actions or advice of regulatory agencies and Alnylam‘s ability to obtain and maintain regulatory aproval for its product candidates, as wel as favorable pricing and reimbursement ; delays, interuptions or failures in the manufacture and suply of Alnylam‘s marketed products or its product candidates ; obtaining, maintaining and protecting intelectual property ; Alnylam‘s ability to manage its growth and operating expenses through disciplined investment in operations ; Alnylam‘s ability to maintain strategic busines colaborations ; Alnylam‘s dependence on third parties for the development and comercialization of certain products ; the outcome of litigation and government investigations ; the risk of future litigation and government investigations ; and unexpected expenditures ; as wel as those risks and uncertainties more fuly discused in the —Risk Factors“ filed with Alnylam‘s most recent periodic report (Quarterly Report on Form 10 - Q or Anual Report on Form 10 - K) filed with the SEC and in its other SEC filings . In adition, any forward - loking statements represent Alnylam‘s views only as of today and should not be relied upon as representing its views as of any subsequent date . Alnylam explicitly disclaims any obligation, except to the extent required by law, to update any forward - loking statements . This presentation references non - GAP financial measures . These measures are not in acordance with, or an alternative to, GAP, and may be diferent from non - GAP financial measures used by other companies . Percentage changes in revenue growth at Constant Exchange Rates, or CER, is a non - GAP financial measure which is presented excluding the impact of changes in foreign curency exchange rates for investors to understand the underlying busines performance . CER represents growth calculated as if the exchange rates had remained unchanged from those used during the prior fiscal year .
Slide 4 — Chief Executive Oficer
4 Yvone Grenstret, M.D. Chief Executive Oficer Overview
Slide 5 — Q2 2026 Results Sumary
5 Q2 2026 Results Sumary Financial Performance $4,70M to $5,10M (+64% YoY @ midpoint) Revised 2026 Total Net Product Revenue Guidance $1,172M (+74% YoY) Q2 Total Net Product Revenues Pipeline Progres Initiated Two Phase 2 Trials • ALN - 640 in Von Wilebrand Disease • Mivelsiran in Down Syndrome - Asociated Alzheimer‘s Disease New AI Partnership to Acelerate Discovery Timelines and Unlock Inovative Oligonucleotide Designs Upcoming Clinical Data Readouts •ALN - HT02 Phase 1 œ EHDN*, October •ALN - 640 Phase 1 (healthy volunters) •ALN - 640 Phase 2 (HT patients) •ALN - 232 Phase 1 (obesity) TR Leadership Q2 Total TR Net Revenues China Distribution Agrement $1,030M (+89% YoY) First Quarter >$1B AMVUTRA Revenues * European Huntington‘s Disease Network Clinical Research Congress, October 22 - 24, 2026 in Krakow, Poland
Slide 6 — Alnylam 2030
6 Alnylam 2030 Acelerating Inovation. Scaling Impact. Scale with Discipline & Agility DRIVE SUSTAINED, PROFITABLE GROWTH • Achieve 25%+ total revenue CAGR through YE 2030 • Deliver ~30% non - GAP operating margin Achieve Global TR Leadership BUILD A DURABLE TR FRANCHISE • Lead TR market in revenue by 2030 and cumulatively acros 5 - year period • Launch best - in - clas, next - gen silencer, nucresiran , in PN by 2028 and CM by 2030 Grow Through Sustainable Inovation DELIVER THERAPIES THAT PREVENT, HALT, OR REVERSE DISEASE • Deliver 2+ new transformative medicines beyond TR with blockbuster potential • Expand to 10 tisue types and > 40 clinical programs • Invest ~30% of revenues in non - GAP R&D, including select external inovation
Slide 7 — Financial Sumary
7 Jef Poulton Chief Financial Oficer Financial Sumary
Slide 8 — Q2 2026 Financial Sumary
8 Q2 2026 Financial Sumary 1 Non - GAP R&D expenses, Non - GAP SG&A expenses, Non - GAP operating income / (los), Non - GAP Operating Margin, and Non - GAP Net Income are non - GAP financial measures that exclude from the coresponding GAP measures costs related to stock - based compensation expense and realized and unrealized gains or loses on marketable equity securities. A reconciliation of these n on - GAP financial measures to the comparable GAP measures, as wel as aditional information regarding our use of non - GAP financi al measures, are included in the Apendix to this presentation and in our pres release dated July 30, 2026, which is acesible in the In ves tors section of our website at w.alnylam.com. 2 CER growth rates represent growth at Constant Exchange Rates, a non - GAP financial measure determined by comparing Q2 2026 perf ormance (restated using Q2 2025 exchange rates) to actual Q2 2025 reported performance. ($ in milions) Q4 2025 Q2 2026 Cash, Cash Equivalents & Marketable Securities (period end) 2,908 3,308 ($ in milions except where noted as percentages) Q2 2025 Q2 2026 Q2 2026 vs Q2 2025 (Reported) Q2 2026 vs Q2 2025 (CER 2 ) Total Net Product Revenues $672 $1,172 74% 74% Net Revenues from Colaborations & Royalties 101 19 17% Colaboration Revenue 61 47 - 23% Royalty Revenue 40 72 79% Total Revenues 74 1,291 67% 67% Total Cost of Gods Sold, Colaborations & Royalties 143 298 Gros Margin on Product Revenues 79% 75% Gros Margin on Total Revenues 82% 7% Non - GAP Combined R&D and SG&A Expenses 1 535 674 26% R&D 274 37 38% SG&A 261 297 14% Non - GAP Operating Income 1 95 318 23% Non - GAP Operating Margin 1 12% 25% Non - GAP Net Income 1 38 252
Slide 9 — 2026 Revised Ful Year Guidance
9 2026 Revised Ful Year Guidance 1 Our 2026 FY Guidance is based upon June 30, 2026 FX rates including 1 EUR = 1.14 USD and 1 USD = 162 JPY 2 CER = constant exchange rate, representing growth calculated as if exchange rates had remained unchanged from those used in 2 02 5. CER is a non - GAP financial measure 3 2026 Non - GAP Combined R&D and SG&A Expenses guidance is a non - GAP financial measure that excludes from the coresponding GAP measure stock - based compensation expense estimated at $30M - $40M in the Prior FY 2026 Guidance and $30M - $380M in the Updated FY 2026 Guidance. Item Prior FY 2026 Guidance Updated FY 2026 Guidance Total Net Product Revenues 1 $4,90 to $5,30 milion $4,70 to $5,10 milion •Total Rare Net Product Revenues (GIVLARI, OXLUMO) $50 to $60 milion Reiterate •Total TR Net Product Revenues (AMVUTRA, ONPATRO) $4,40 to $4,70 milion $4,20 to $4,50 milion Net Product Revenues Growth vs. 2025 at Reported FX Rates 1 64% to 7% 57% to 71% Net Product Revenues Growth vs. 2025 at constant exchange rates (i.e., operational growth) 2 64% to 7% 57% to 70% Net Revenues from Colaborations & Royalties $40 to $50 milion $575 to $625 milion Non - GAP Combined R&D and SG&A Expenses 3 $2,70 to $2,80 milion Reiterate
Slide 10 — Comercial Highlights
10 Tolga Tanguler Chief Comercial Oficer Comercial Highlights
Slide 11 — Wel Positioned to Deliver on 2030 TR Leadership Ambitions
1 Wel Positioned to Deliver on 2030 TR Leadership Ambitions Select U.S. analogs are 2nd+ to market with diferentiated mechanism of action, specialty/rare, Buy & Bil, or part of direct co mpetitive set. 1 Evaluate Pharma. 2 ALNY colaboration finance reporting based estimates. 3 VYNDA and BEYONTRA revenues are calculated estimates based on IQVIA data. 4 U.S. AMV CM sales are based on split of the reported demand betwen PN+CM each month from ADS $2.49B $1.23B 2025 $4.35B $1.15B 2026 2030 $3.71B $5.50B +25% CAGR TR - 2025 Actual TR - MidPoint Guidance Other Revenues Other Revenue - Midpoint Total 2030 Goal Our Ambition Our Progres WINREVAIR 1 ATRUBY 1 LEQVIO 2 OCREVUS 1 SAPHNELO 1 VYVGART 1 VYNDA family 1 Quarters Post Launch 0 1 2 3 4 5 AMVUTRA in ATR - CM 4 Quarterly Revenue
Slide 12 — Continued Comercial Execution in Q2 2026
12 Continued Comercial Execution in Q2 2026 1 With FX impact. For growth at CER = constant exchange rate œ se the Financial Sumary slide for more information. $1.17B Combined Net Product Revenues +74% YoY growth 1 vs. Q2‘25 +13% QoQ growth 1 vs. Q1‘26 Q2 2026 Overal Portfolio Rare Franchise TR Franchise
Slide 13 — Robust Patient Demand Fuels Sustained ATR
13 1 CER = Constant exchange rate, which is a non - GAP financial measure that represents growth calculated as if exchange rates had remained unchanged from those used during 2025 œ se the Financial Sumary slide for more information. Robust Patient Demand Fuels Sustained ATR - CM Growth $1.03B Total TR Global Q2 2026 Net Product Revenues Q2 2026 TR Franchise Highlights QoQ % Growth YoY % Growth U.S. 15% 14% ROW 7% 31% Global 13% 89% $361M $530M $642M $703M $809M $131M $15M $185M $187M $203M $2M $30M Q2 2025 $12M $27M Q3 2025 $12M $20M Q4 2025 $10M $10M Q1 2026 $10M $9M Q2 2026 $54M $724M $859M $910M $1,030M +89% +13% U.S. ONPATRO U.S. AMVUTRA ROW ONPATRO ROW AMVUTRA • U.S. 14% increase driven by strong demand growth from ATR - CM launch partialy ofset by lower net price • ROW 31% increase primarily driven by uptake in ATR - CM sales in Japan and Germany, continued ATR - PN patient growth, both partialy ofset by lower net price primarily driven by German launch in ATR - CM §͑ Ѝ͕͑ ϙŽŜϟϙ§͑ Ѝ͔͑ ϙϼ“ĺ“ϽϙcĖČēīĖČēťŜ • U.S. 15% increase driven by strong Q2 demand growth, partialy ofset by $21M inventory impact due to chanel inventory reduction from 21.5 to 19 days on hand during Q2, and modest price reduction ($2M) • ROW 7% increase driven by uptake in ATR - CM sales in Japan, UK and Germany, partialy of - set by lower net price related to ongoing CM launches §͑ Ѝ͕͑ ϙŽŜϟϙ§͐ Ѝ͕͑ ϙϼ§ĺ§ϽϙcĖČēīĖČēťŜ +$106M U.S. TR vs. Q1 +$14M ROW TR vs. Q1 +$120M Global TR vs. Q1
Slide 14 — First Half 2026 U.S. TR Revenue Dynamics
14 First Half 2026 U.S. TR Revenue Dynamics $58M $129M Inv. - $5M Inv. $6M Demand $654M $713M $819M Price Q1‘26 Demand - $21M Q2‘26 Price - $2M Q4‘25 +$59M +$106M Q1 demand impacted by seasonal phasing Q2 reflects a reaceleration in demand
Slide 15 — 15
15 Aproved for the treatment of ATR - CM in adults in the U.S. Aproved for the treatment of hATR - PN in adults in the U.S. Consistency in treatment efect with or without background stabilizer Dosing frequency AMVUTRA Delivers a Highly Diferentiated Clinical Profile tafamidis acoramidis eplontersen Daily (1 capsule) Daily (2 capsules, twice a day) Monthly (self - administered autoinjector) Quarterly (HCP œadministered prefiled syringe) ض ض ض ض ض ض
Slide 16 — Established as
16 Insights Reinforcing Our Long - Term TR Strategy AMVUTRA Established as 1L Option AMVUTRA gaining traction as compeling 1L option in just five quarters since ATR - CM launch Favorable Competitive Developments Delay in expected stabilizer genericization and CARDIO - TRansform topline results reinforce AMVUTRA oportunity 2L Inflow Volume Normalizing Growth of inflow in stabilizer progresor patients normalizing from concentration early in ATR - CM U.S. launch Acelerating Category Growth Unmet ned driving earlier diagnosis and treatment of patients and growth in number of physicians and systems treating ATR - CM
Slide 17 — Broad &
17 Driving breadth of prescribers is key to unlocking our next wave of growth Drivers of Future TR Growth Oportunity Maintaining Broad & Favorable Aces We continue to experience broad coverage and eficient patient aces, with no meaningful reimbursement headwinds Investing to Expand Prescriber Base Driving 1L HCP and Patient Preference We are capturing >50% of new patient starts from AMVUTRA - experienced prescribers From ATR - CM launch through the end of Q2, we have aded >1,70 new prescribers ~1/3 of al active TR treaters have prescribed AMVUTRA We are investing further to capitalize on the much larger expansion oportunity ahead
Slide 18 — Pipeline
18 Pushkal Garg, M.D. Chief Research & Development Oficer Pipeline
Slide 19 — AMVUTRA: Powerful Eficacy from HELIOS
19 AMVUTRA: Powerful Eficacy from HELIOS - B Suports First - Line Use 1 Garcia - Pavia, et al. ESC 2025; 2 NEJM 2024 (BNP and Age)/Data on file (6 - MWT); 3 Abovich, et al. ESC Heart Failure 2026. Al - cause mortality (ACM) includes heart transplantation and left ventricular asist device placement, and CV events include CV - related hospitalizations and urgent heart failure visits. Large reductions in al - cause mortality and cardiovascular events Benefits greatest when initiated early in disease Consistent efect on top of background medications, including stabilizers Quarterly dosing that suports adherence Time - to - First CV Event or ACM 1 Time to ACM 1 Early Patients Realize Greatest Benefit 2 ACM and Recurent CV Events ACM and Recurent CV Events Consistent Efect Acros Background Meds 2
Slide 20 — Ongoing Nucresiran TRITON Phase 3 Program
20 Ongoing Nucresiran TRITON Phase 3 Program Nucresiran is an investigational therapeutic in development for the treatment of ATR amyloidosis. The safety and eficacy of nu cresiran have not ben established or aproved by the FDA, EMA or any other health authority. Targeting Launch by 2028 •Randomized, open - label study of nucresiran versus vutrisiran internal reference (N ~125) •Primary endpoint of mNIS+7 at Month 9 in nucresiran versus APOLO placebo (similar to HELIOS - A) œContinued data colection through Month 18 Targeting Launch by 2030 •Randomized, double - blind, event - driven outcomes study of nucresiran versus placebo œEnrolment expanded from N ~1,250 to ~1,750 •Primary endpoint of al - cause mortality and recurent CV events Next - generation silencer with potential for greater TR knockdown, improved eficacy, and bianual dosing
Slide 21 — Key Questions for Cardio
21 Patient characteristics disease severity acros subgroups; background meds Key Questions for Cardio - TRansform Data Presentation TR knockdown depth and time to achieve; variability Study execution completenes of folow - up Outcomes impact on endpoint components (CVM, CV events) as wel as ACM; acrual of events over time; treatment efect over time; acros subgroups (e.g., disease severity) Safety & tolerability adherence to study drug; competing risks Alnylam has time to consider eplontersen results and adjust TRITON - CM study, if waranted
Slide 22 — High Confidence in TRITON
2 High Confidence in TRITON - CM Based on Data & Experience 1 HELIOS - B and APOLO - B Our Molecule RNAi >95% TR knockdown 2 prior studies showing efect on top of stabilizers 1 Our Study ~1,750 patients Event driven Enriched for patients most likely to benefit Our Track Record >15 years in TR drug development Dep patient - level insights from prior studies Meticulous study execution driving sucesful results (e.g., HELIOS - B)
Slide 23 — Benefit on Top of Stabilizers Suported by Strong Clinical Data
23 Benefit on Top of Stabilizers Suported by Strong Clinical Data 1 Pre - specified subgroup analysis of secondary endpoint; includes OLE. 2 Pre - specified analysis of component of composite endpoint (exploratory endpoint); includes OLE. 3 HELIOS - A. 4 APOLO. 5 Polydefkis, et al. ISA 2018 KD: knockdown; Steady state KD numbers are based on M18 data for patisiran and vutrisiran; The proportion of patients are mod el - based aproximate estimates and calculated using observed median & IQR and lognormal distribution asumption Patisiran is not aproved for ATR - CM in any region. 0.25 0.5 1 2 Favors drug Favors placebo HR (95% CI) APOLO - B (N=91) 2 24 - month folow - up HR=0.56 (0.2, 1.4) HELIOS - B (N=259) 1 Up to 42 - month folow - up HR=0.59 (0.32, 1.08) Al - Cause Mortality in Patients on Background Stabilizer ATR Cardiomyopathy Steady state KD (median) Estimated proportion of pts w/ TTR KD ≥ 5 Vutrisiran 3 91% ~82% Patisiran 4 89% ~84% hATR Polyneuropathy Two independent studies with diferent RNAi therapeutics demonstrated reduction of ACM on top of background stabilizers
Slide 24 — RNAi Drives Dep, Consistent Knockdown of TR
24 RNAi Drives Dep, Consistent Knockdown of TR Eplontersen data: NEURO - TRansform; Vutrisiran data: HELIOS - A; Nucresiran data: model predicted using Phase 1 data (30 mg Q6M). Steady state KD numbers are based on wek 35 data for eplontersen and M18 data for vutrisiran and nucresiran; The proportion of patients are model - based aproximate estimates and calculated using observed (eplontersen and vutrisiran) or predicted (nucresiran) median & IQR and lognormal distribution asumption. 1 Polydefkis, et al. ISA 2018 Median Knockdown (%) 0 10 20 30 40 50 60 70 80 90 10 Eplontersen Vutrisiran Nucresiran 67% 82% 9% 3% 18% 1% % <80% % ≥80% 0 10 20 30 40 50 60 70 80 90 10 Eplontersen Vutrisiran Nucresiran 84% 91% 95% Estimated Percent Above or Below Threshold 1
Slide 25 — Industry Leading Pipeline of RNAi Therapeutics
25 Industry Leading Pipeline of RNAi Therapeutics 1 Out - licensed with milestones and/or royalties; 2 Partnered, Alnylam - led development with U.S. profit split and milestones/royalties ex - U.S.; 3 Partner - led with profit split; 4 Partnered, Alnylam - led with profit split; Alnylam - owned, - led, or œco - developed PHASE 1 PHASE 2 PHASE 3 TR Nucresiran Nucresiran CARDIOVASCULAR Zilebesiran 2 Zilebesiran REVERSIR 2 METABOLIC Rapirosiran (ALN - HSD) 1 ALN - ANG3 1 ALN - 4324 (GRB14) ALN - PNP 1 ALN - CIDEB 1 ALN - 232 (ACVR1C) ALN - 62 (INHBE) ALN - APOC3 1 NEUROSCIENCE Cemdisiran 1 Mivelsiran Mivelsiran ALN - SOD 3 ALN - HT02 4 ALN - 528 (MAPT) 4 ALN - SNCA 1 HEMATOLOGY Cemdisiran 1 ALN - 640 (PLG) ALN - 640 (PLG) AG - 236 (ALN - TMP) 1 ALN - CFB 1 OTHER Cemdisiran 1 Elebsiran 1 ALN - BCAT ALN - 4285 ALN - 4915 ALN - F1202 1 ATR Amyloidosis with Cardiomyopathy hATR Amyloidosis with Polyneuropathy Hypertension Hypertension Metabolic Dysfunction - Asociated Steatohepatitis (MASH) Dyslipidemia Type 2 Diabetes Melitus Non - Alcoholic Faty Liver Disease (NAFLD) MASH Myasthenia Gravis Cerebral Amyloid Angiopathy Alzheimer‘s Disease SOD1 Amyotrophic Lateral Sclerosis Huntington‘s Disease Alzheimer‘s Disease Paroxysmal Nocturnal Hemoglobinuria Hereditary Hemorhagic Telangiectasia Polycythemia Vera Paroxysmal Nocturnal Hemoglobinuria Hepatitis D Virus Infection Diabetic Kidney Disease Hepatocelular Carcinoma Geographic Atrophy Healthy Volunters Obesity & Weight Management Parkinson‘s Disease Healthy Volunters Healthy Volunters Obesity & Weight Management Von Wilebrand Disease
Slide 26 — 26
26 * Asuming positive phase 3 data and regulatory aproval Expect Significant Clinical Milestones Over Next Two Years 3 - 4 New IND Filings Per Year 4 Key data readouts 3 Pivotal studies ongoing 2026 5+ Key data readouts 4+ Pivotal studies ongoing 2027 5+ Key data readouts 5+ Pivotal studies ongoing 1 Product launch* 2028
Slide 27 — 2026 Pipeline Goals to Drive Our Next Phase of Growth
27 2026 Pipeline Goals to Drive Our Next Phase of Growth Products mentioned above are not aproved for any indication and conclusions regarding the safety or efectivenes of these d rug s have not ben established. Nucresiran ATR Amyloidosis Advance TRITON - CM Phase 3 Trial Ongoing Advance TRITON - PN Phase 3 Trial Ongoing Zilebesiran Hypertension Advance ZENITH Phase 3 Trial Ongoing Mivelsiran Cerebral Amyloid Angiopathy Complete Enrolment of cAPricorn - 1 Phase 2 Trial H1 Alzheimer‘s Disease Initiate Phase 2 Trial H1 ALN - 640 Bleding Disorders Initiate Phase 2 Trial in Second Bleding Disorder H1 Phase 1 Data in Healthy Volunters H2 Phase 2 Results in HT H2 ALN - 4324 Type 2 Diabetes Melitus Initiate Phase 2 Trial H1 ALN - HT02 Huntington‘s Disease Phase 1 Data H2 ALN - 232 Obesity & Weight Management Phase 1 Data H2 Aditional Programs File 3 - 4 INDs 2026
Slide 28 — Q2 2026 Financial ResultsQ&A Sesion
28 Q2 2026 Financial ResultsQ&A Sesion
Slide 29 — 29
29